PharmaDossierIndependent biopharma information, guidance, and source-cited analysis.

PHARMApharmadossier

Topic

Nephrology

Kidney disease drugs, outcomes evidence, payer coverage, dialysis-adjacent access, and affordability.

5 articles·Lives underPricing & Access Evidence·Last updated 2026-08-17

Pricing & Access· August 17, 2026 · 25 min read

Tavneos on Formularies as FDA Moves to Withdraw: The Coverage Dilemma

By Ran Chen#Coverage Access #Prior Authorization #Payer Policy

Specialty· August 15, 2026 · 25 min read

Kidney Transplant Immunosuppression: Part B-ID Cliff, Tacrolimus, & Access

By Ran Chen#Nephrology #Medicare Part B #Coverage Access

Evidence· July 10, 2026 · 17 min read

Calcineurin Inhibitor Adverse Events in FAERS: 275,000 Reports and Key Safety Signals

By Ran Chen#Real-World Evidence #Postmarketing Requirements #Label Warnings

Specialty· July 9, 2026 · 17 min read

IgA Nephropathy Access: Trutakna, Filspari, Tarpeyo, Fabhalta, and Voyxact

By Ran Chen#Nephrology #Specialty Pharmacy #Prior Authorization

Evidence· July 1, 2026 · 17 min read

ACE Inhibitors and ARBs in FAERS: 46,000 Reports in 2025 and the Core Signals

By Ran Chen#Hypertension #Cardiovascular #Real-World Evidence